Revenue: As of FY2026 Q2, the actual value is USD 0, missing the estimate of USD 126.5 K.

EPS: As of FY2026 Q2, the actual value is USD -0.07, beating the estimate of USD -0.235.

EBIT: As of FY2026 Q2, the actual value is USD -3.673 M.

Cash and Cash Equivalents

Aprea Therapeutics, Inc. reported cash and cash equivalents of $41,233,428 as of June 30, 2026, an increase from $14,599,347 as of December 31, 2025. The company projects that these cash and cash equivalents will be sufficient to cover projected operating expenses and capital expenditure requirements into the first quarter of 2028.

Operating Loss

For the second quarter ended June 30, 2026, Aprea Therapeutics, Inc. reported an operating loss of - $4,032,180, compared to an operating loss of - $3,387,773 for the second quarter of 2025. For the six months ended June 30, 2026, the operating loss was - $7,462,592, compared to - $7,473,355 for the comparable period in 2025.

Research and Development (R&D) Expenses

R&D expenses for the second quarter of 2026 were $2,462,042, an increase from $1,912,213 for the second quarter of 2025. For the six months ended June 30, 2026, R&D expenses were $4,073,209, down from $4,395,279 in the prior year period.

General and Administrative (G&A) Expenses

G&A expenses were $1,570,138 for the second quarter of 2026, compared to $1,593,671 for the second quarter of 2025. For the six months ended June 30, 2026, G&A expenses were $3,389,383, compared to $3,358,650 in the prior year period.

Grant Revenue

Aprea Therapeutics, Inc. reported no grant revenue for the second quarter and six months ended June 30, 2026, which is a decrease compared to $118,111 and $280,574 for the respective periods in 2025.

Other Income (Expense)

Net interest income was $358,923 for Q2 2026, up from $178,027 for Q2 2025, and $493,707 for the six months in 2026 versus $382,753 in 2025. Other income was $79,000 for Q2 2026 and for the six months in 2026, with $0 reported for both periods in 2025. The company reported a foreign currency gain of $2,953 for Q2 2026, compared to a loss of - $29,124 for Q2 2025, and a gain of $10,664 for the six months in 2026 versus a loss of - $80,927 in 2025.

Net Loss

Net loss for the second quarter of 2026 was - $3,591,304, compared to - $3,238,870 for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $6,879,221, compared to - $7,171,529 for the comparable period in 2025.

Net Loss Per Share (Basic and Diluted)

Net loss per basic share was - $0.07 for the second quarter of 2026, compared to - $0.53 for the second quarter of 2025. For the six months ended June 30, 2026, net loss per basic share was - $0.20, compared to - $1.19 for the comparable period in 2025.

Weighted-Average Common Shares Outstanding

Weighted-average common shares outstanding were 53,483,504 for the second quarter of 2026, significantly higher than 6,083,329 for the second quarter of 2025. For the six months ended June 30, 2026, shares outstanding were 34,191,653, compared to 6,038,845 in the prior year period.

Total Comprehensive Loss

Total comprehensive loss for the second quarter of 2026 was - $3,583,221, compared to - $3,240,551 for the second quarter of 2025. For the six months ended June 30, 2026, total comprehensive loss was - $6,862,124, compared to - $7,172,567 for the comparable period in 2025.

Operational Metrics

Enrollment in the Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating, with active clinical sites expanding from three to ten. Aprea Therapeutics, Inc. plans to advance APR-1051 in uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) as a single agent, and in combination with standard of care in HPV-positive head and neck cancer and colorectal cancer. During 2025, Aprea Therapeutics, Inc. determined the recommended Phase 2 monotherapy dose (RP2D) of 1,100 mg once daily for ATRN-119 in the ABOYA-119 Phase 1/2a dose-escalation study, which has since been closed to focus resources on APR-1051. The company is considering further ATRN-119 development in combination approaches and is in discussions with academic centers. Aprea Therapeutics, Inc. also has an early-stage macrocyclic DYRK1A/B inhibitor program that could potentially enter IND enabling studies in the fourth quarter of 2026, subject to available resources.

Outlook / Guidance

Aprea Therapeutics, Inc. expects to report the next clinical data update from the ACESOT-1051 trial at a medical meeting in the fourth quarter of 2026. The company anticipates enrollment in ACESOT-1051 to reach 6 to 10 patients per month by Q4 2026, potentially increasing the pace of clinical data generation. Completion of dose escalation and backfill expansion for APR-1051 in USC and Cyclin E-overexpressing PROC is anticipated in the second quarter of 2027.